Search

Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?

During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.

Read more

Trial membership

Are you interested in connecting with EHA and our vibrant community, but you're not yet ready to apply for membership?

By becoming an EHA guest, you can enjoy 60 days of free access to:

The European Hematology Curriculum
Select courses on EHA Campus
You'll…

Read more

Junior membership

If you're at an early stage in your career, junior membership can be a great way to:

Expand your knowledge
Make connections
Access EHA's early career opportunities
Stay up to date with the latest developments
As a junior member, you can also apply for EHA…

Read more

Emeritus membership

If you're a scientific researcher, physician, or healthcare-affiliated professional who's now retired or is close to retirement, you can join EHA at a reduced rate.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Healthcare-affiliated professional membership

You don't need to be scientific researcher or a physician to join our vibrant community.

Read more

EHA Ranking 2025

The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version

Position 
Company 
Priority points 
Corporate Level 


Johnson & Johnson  
1. 488,82  
Platinum  


Bristol Myers Squibb  
1.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more